Lv21
160 积分 2024-09-24 加入
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
2天前
已完结
Multiple myeloma
3天前
求助中
Use of long-term corticosteroids in patients treated with CAR T-cell therapy
20天前
已完结
Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting
20天前
已完结
Expression of Uptake Hydrogenase and Molybdenum Nitrogenase in Rhodobacter capsulatus Is Coregulated by the RegB-RegA Two-Component Regulatory System
20天前
已完结
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
21天前
已完结
MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
1个月前
已完结
Zevorcabtagene Autoleucel: First Approval
1个月前
已完结
皖公网安备34019202002308
